Quest Diagnostics has introduced a new pharmacogenomic (PGx) laboratory testing service designed to assist healthcare providers in understanding their patients’ genetic responses to specific medications.
This service is intended to support clinicians in selecting appropriate drugs and determining optimal dosages.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The PGx offering spans various medical fields, including neurology, psychiatry, oncology, cardiology, pain management, rheumatology, and the transplant recipient space.
Research indicates that PGx testing can reduce the risk of therapeutic failures and adverse drug interactions (ADIs) while also minimising unnecessary medication costs and expenses related to drug-related complications.
The service consists of 17 genes and four human leukocyte antigen (HLA) alleles, focusing on genes with established gene-drug associations and medical utility.
The genes have clinically actionable associations that are informed by expert organisations such as the US Food and Drug Administration (FDA), Clinical Pharmacogenetics Implementation Consortium (CPIC) and ClinPGx.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataQuest鈥檚 service provides a report that includes genotype (diplotype) and predicted phenotypic responses, along with medication guidance linked to a personalised report developed by Coriell Life Sciences (CLS), now InformedDNA.
Healthcare providers will also have access to CLS鈥� clinical decision support tool, GeneDose LIVE, that enables a thorough assessment of a patient’s medication regimen, evaluating both genetic and non-genetic risks in relation to all prescribed therapies.
The report is based on current, evidence-based gene-drug associations, offering recommendations.
An alternative option is available that includes only the genotype and predicted phenotypic response.
Quest Diagnostics US speciality genetics and genomics services general manager Steven Keiles said: 鈥淥ur goal for this PGx offering from Quest Diagnostics and Coriell Life Sciences is to help providers more efficiently leverage genetic insights to help guide prescription decisions and decrease trial-and-error while improving outcomes.鈥�
Patients can obtain testing by presenting a requisition from their healthcare provider at one of the company鈥檚 2,000 patient service centres located throughout the US.
Additionally, Quest offers home collection services through at-home phlebotomy for patients facing scheduling conflicts, distance issues, or other barriers to in-office testing.
In February, Grail partnered with Quest Diagnostics to provide US healthcare providers access to Galleri multi-cancer early detection.
